StockNews.com started coverage on shares of Oragenics (NYSE:OGEN – Free Report) in a report published on Tuesday. The firm issued a sell rating on the stock.
Oragenics Trading Up 29.6 %
NYSE OGEN traded up $0.32 during trading hours on Tuesday, hitting $1.40. The company had a trading volume of 1,739,745 shares, compared to its average volume of 185,378. The firm has a 50 day moving average of $1.25. The stock has a market cap of $6.27 million, a P/E ratio of -0.16 and a beta of 0.50. Oragenics has a 1-year low of $0.86 and a 1-year high of $7.74.
Oragenics (NYSE:OGEN – Get Free Report) last announced its earnings results on Wednesday, May 15th. The company reported ($0.70) earnings per share (EPS) for the quarter.
Hedge Funds Weigh In On Oragenics
About Oragenics
Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.
Featured Articles
- Five stocks we like better than Oragenics
- How to Read Stock Charts for Beginners
- Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
- Investing in large cap stocks: Diving into big caps
- MarketBeat Week in Review – 8/5 – 8/9
- What Are Dividend Contenders? Investing in Dividend Contenders
- The Cannabis Sector: Profitability Takes Center Stage
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.